The expression of selected molecular markers of immune tolerance in psoriatic patients

Bartosińska, Joanna; Purkot, Joanna; Kowal, Małgorzata; Michalak-Stoma, Anna; Krasowska, Dorota; Chodorowska, Grażyna; Giannopoulos, Krzysztof

doi:10.17219/acem/78020

Cited by 10 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the lack of difference in sHLA-G concentration between psoriatic patients and healthy volunteers might suggest an insufficient mechanism which could limit immune responses and suppress pathologic immunity. Interestingly, in our previous study we did not find any difference in the mRNA HLA-G expression between the psoriatic patients and controls [20]. Both Aractingi et al [24] and Cardili et al [25] observed enhanced HLA-G expression within the psoriatic lesions, which may be suggestive of some modulating role of HLA-G+ T cells at the site of inflammation.…”

Section: Discussionmentioning

confidence: 70%

“…The soluble form of PD-1, however, acts as a decoy receptor able to bind and neutralize PD-1/PDL1 [4, 5]. In our recent studies we have found that both the expression of PDCD1 mRNA in peripheral blood mononuclear cells [20] and the expression of PD-1 protein on CD4+ and CD8+ T cells were significantly decreased in psoriatic patients both with and without arthritis [21]. Thus, the compromised PD-1 function on CD4 + and CD8+ T cells might indicate inappropriate activation status and suggest dysregulation of the immune suppression mechanisms, which may lead to abnormal, persistent T cell activation and cytokine production in psoriasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients

Bartosińska

Michalak-Stoma

Kowal

et al. 2019

pdia

Self Cite

View full text Add to dashboard Cite

A b s t r a c tIntroduction: Circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) take part in modulating immune tolerance causing disturbances in the molecular mechanisms responsible for maintenance of balance between effector and regulatory components of the immune system. Since their cell-surface expression levels were found to be changed in lesional and/or non-lesional skin of psoriatic patients, analysis of soluble PD-1, NRP-1 and HLA-G concentrations sheds more light on their role in detecting unbalanced immune tolerance in psoriasis. Aim: To assess soluble PD-1, NRP-1 and HLA-G concentrations in psoriasis. Material and methods: The study included 57 psoriatic patients and 29 controls. Duration of psoriasis was in the range 1 to 55 years; the median was 19 years. The plasma concentrations of soluble HLA-G (sHLA-G), soluble NRP-1 (sNRP-1) and soluble PD-1 (sPD-1) were examined using the ELISA method. Severity of the skin lesions was assessed by means of Psoriasis Area Severity Index (PASI), body surface area (BSA) and Physician Global Assessment (PGA). Results: Psoriasis Area Severity Index in the studied group was in the range 3 to 43; the median was 12. Body surface area was in the range 2-75%; the median was 15%. The median value of PGA was 3. Soluble NRP concentration was significantly higher in the psoriatic patients (median: 1.59 pg/ml; range: 0.67-2.62 pg/ml) than in the control group (median: 1.35 pg/ml; range: 0.05-2.61 pg/ml) (p = 0.010). Soluble PD-1 and sHLA-G concentrations were not significantly different between the studied and control groups (p = 0.094 and p = 0.482, respectively). Conclusions: Increased concentrations of sNRP-1 and unchanged values of sHLA-G and sPD-1 concentrations may be indicative of impaired immune tolerance mechanisms in psoriasis.

show abstract

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients

Bartosińska

Michalak-Stoma

Kowal

et al. 2019

pdia

Self Cite

View full text Add to dashboard Cite

show abstract

“…A total of 119 studies met the selection criteria and were included. Of these, 19 studied clinical markers [ 18 – 36 ], 69 studied laboratory markers [ 27 , 37 , 38 , 40 – 55 , 57 – 73 , 75 – 96 , 124 – 133 ], and 32 studied genetic markers [ 97 – 113 , 115 – 123 , 134 – 139 ]. One study described both clinical and laboratory markers [ 27 ].…”

Section: Resultsmentioning

confidence: 99%

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review

et al. 2021

View full text Add to dashboard Cite

Twenty to thirty percent of psoriasis (Pso) patients will develop psoriatic arthritis (PsA). Detection of Pso patients that are (at risk for) developing PsA is essential to prevent structural damage. We conducted a systematic search of five bibliographic databases, up to May 2020. We searched for studies assessing markers (clinical, laboratory, genetic) associated with the development or presence of PsA in Pso patients. Study selection and quality assessment of the included studies was performed, followed by a qualitative best evidence synthesis to determine the level of evidence for a marker and its association with concomitant/developing PsA in Pso. Overall, 259 possible markers were identified in 119 studies that met the inclusion criteria. Laboratory markers related to inflammation and bone metabolism reached a strong level of evidence for the association (not prediction) of PsA in Pso. Only CXCL10 showed strong evidence for a positive predictive value for PsA in Pso. The importance of timely detecting PsA in a Pso population, and finding more (bio)markers contributing to early detection, remains high.

show abstract

“…Various studies have examined the correlation between PD-1 expression and CPP [ 3 , 4 , 5 , 6 , 7 , 18 ]. PD-1, a cell surface membrane receptor expressed on various inflammatory cells, transduces inhibitory signals to immune cells, including effector T cells, and promotes Treg activity [ 3 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…Dysfunctional regulatory T (Treg) cells disrupt immune tolerance, which leads to the induction of autoimmune and auto-inflammatory diseases, such as psoriasis [ 2 ]. In addition to the immune-suppressing cytokines released from Treg cells, some T cell surface molecules, including cytotoxic T lymphocyte-associated antigen 4 (CTLA4), neurophilin-1, human leukocyte antigen G, and the programmed cell death protein-1 (PD-1) that interacts with the programmed cell death ligand (PD-L1), play critical roles in immune tolerance [ 3 ]. Dysfunctional T cell surface molecules cannot inhibit the activity of inflammatory cells in patients with psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression

Jung

Yang

Bang

et al. 2021

JCM

View full text Add to dashboard Cite

Several studies have determined the correlation between programmed cell death protein-1 (PD-1) and chronic plaque psoriasis (CPP). However, limited studies have assessed the association between PD-1 expression and the clinicoprognostic and distinct clinicopathological characteristics of CPP and guttate psoriasis (GP). Twenty-nine patients with skin biopsy-confirmed CPP were recruited at the Asan Medical Center between January 2018 and June 2020, and 33 patients with biopsy-confirmed GP were enrolled between January 2002 and June 2020. The clinicoprognostic and histopathological characteristics were analyzed according to immunohistochemical PD-1 expression in the epidermal or dermal inflammatory infiltrates. The CPP and GP lesions were divided into PD-1-low and PD-1-high groups. The CPP epidermal PD-1-high group had typical histopathological changes and significantly higher psoriasis area and severity index scores (p = 0.014) and disease duration (p = 0.009) than the epidermal PD-1-low group. In patients with GP, compared with the dermal PD-1-high group, the dermal PD-1-low group exhibited significantly higher disease duration (p = 0.002) and relapse rate of plaque psoriasis (p = 0.005) and significantly lower relapse-free survival (p = 0.016). Upregulated epidermal PD-1 expression was correlated with the chronicity and severity of CPP, while downregulated dermal PD-1 expression was correlated with poor prognosis of GP.

show abstract

The expression of selected molecular markers of immune tolerance in psoriatic patients

Cited by 10 publications

References 17 publications

Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients

Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review

Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression

Contact Info

Product

Resources

About